AnaptysBio, Inc. (ANAB) Analysts See $-0.66 EPS

October 13, 2018 - By Richard Conner

Analysts expect AnaptysBio, Inc. (NASDAQ:ANAB) to report $-0.66 EPS on November, 6.They anticipate $0.21 EPS change or 46.67 % from last quarter’s $-0.45 EPS. After having $-0.57 EPS previously, AnaptysBio, Inc.’s analysts see 15.79 % EPS growth. The stock decreased 1.26% or $1 during the last trading session, reaching $78.64. About 355,536 shares traded. AnaptysBio, Inc. (NASDAQ:ANAB) has risen 165.85% since October 13, 2017 and is uptrending. It has outperformed by 150.23% the S&P500.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company has market cap of $2.06 billion. The company??s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It currently has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

More notable recent AnaptysBio, Inc. (NASDAQ:ANAB) news were published by: Seekingalpha.com which released: “AnaptysBio closes $239M stock offering” on September 28, 2018, also Fool.com with their article: “Here’s Why AnaptysBio Rose 12.6% in September” published on October 11, 2018, Seekingalpha.com published: “AnaptysBio prices public offering of common stock” on September 26, 2018. More interesting news about AnaptysBio, Inc. (NASDAQ:ANAB) were released by: Globenewswire.com and their article: “Research Report Identifies AnaptysBio, Imperial Oil, Norbord, 3D, Apple Hospitality REIT, and Pinnacle Foods with …” published on October 08, 2018 as well as Globenewswire.com‘s news article titled: “AnaptysBio Announces Pricing of Public Offering of Common Stock” with publication date: September 25, 2018.

AnaptysBio, Inc. (NASDAQ:ANAB) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>